An Open-Label, Phase I Dose Escalation Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer.

Trial Profile

An Open-Label, Phase I Dose Escalation Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2013

At a glance

  • Drugs MVA-BN-PRO (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Bavarian Nordic media release. Results were also briefly summarised in the media release.
    • 25 Jan 2012 Additional lead trial investigator (Bandman O) identified as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Planned end date changed from 1 Aug 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top